Fresenius News Not All Bad For Affymax’s Omontys
This article was originally published in The Pink Sheet Daily
Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.
You may also be interested in...
Takeda/Affymax Recall ESA Omontys After Patient Deaths
Takeda had soured on the drug in Japan as it shifted away from renal therapies, but the drug’s future is now in doubt.
ESRD Market Snapshot: The Price Has To Be Right
The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.
Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers
With FDA’s March 27 approval of peginesatide to prevent anemia in CKD patients on dialysis, Affymax will focus initially on marketing to smaller, price-conscious dialysis providers. But the biotech also expects to do business with Fresenius and, to a lesser degree, Davita.